Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.

被引：1

作者：

Dreyling, Martin H.

Leppa, Sirpa

Comeau, Terrance

Kosinova, Marina

Lenz, Georg

Nagler, Arnon

Heo, Dae Seog

Oh, Sung Yong

Huang, Liping

Wirtz, Oliver

Miriyala, Ashok

Garcia-Vargas, Jose E.

Childs, Barrett H.

Zinzani, Pier Luigi

机构：

[1] Klin Univ Munchen LMU, Medizin Klin & Poliklin 3, Munich, Germany

[2] Helsinki Univ Cent Hosp Canc Ctr, Helsinki, Finland

[3] St Johns Hosp, St John, NB, Canada

[4] Kemerovo Reg Reg Clin Hosp, Kemerovo, Russia

[5] Munster Univ Clin, Translat Oncol Med Clin, Munster, Germany

[6] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel

[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[8] Dong A Univ Coll Med, Dept Internal Med, Busan, South Korea

[9] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[10] Bayer AG, Pharmaceut Div, Wuppertal, Germany

[11] Univ Bologna, Inst Hematol L E A Seragnoli, Bologna, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.7570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7570

引用

页数：1

共 50 条

[1] Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
Provencio Pulla, M.
Santoro, A.
Mollica, L.
Leppa, S.
Follows, G.
Lenz, G.
Kim, W. S.
Nagler, A.
Panayiotidis, P.
Demeter, J.
Ozcan, M.
Kosinova, M.
Bouabdallah, K.
Morschhauser, F.
Ishida, T.
Huang, L.
Garcia-Vargas, J.
Childs, B. H.
Zinzani, P. L.
Dreyling, M.
ANNALS OF ONCOLOGY, 2017, 28
[2] Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study
Dreyling, Martin
Santoro, Armando
Mollica, Luigina
Leppa, Sirpa
Follows, George A.
Lenz, Georg
Kim, Won Seog
Nagler, Arnon
Panayiotidis, Panayiotis
Demeter, Judit
Ozcan, Muhit
Kosinova, Marina
Bouabdallah, Krimo
Morschhauser, Franck
Stevens, Don A.
Trevarthen, David
Giurescu, Marius
Kupit, Lisa
Yin, Shuxin
Hiemeyer, Florian
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
CANCER RESEARCH, 2017, 77
[3] Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study
Dreyling, M.
Santoro, A.
Mollica, L.
Leppa, S.
Follows, G. A.
Lenz, G.
Kim, W. S.
Nagler, A.
Panayiotidis, P.
Demeter, J.
Ozcan, M.
Kosinova, M.
Bouabdallah, K.
Morschhauser, F.
Stevens, D. A.
Trevarthen, D.
Giurescu, M.
Kupit, L.
Childs, B. H.
Zinzani, P. L.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 12 - 12
[4] Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study
Santoro, Armando
Mollica, Luigina
Leppa, Sirpa
Follows, George A.
Lenz, Georg
Kim, Won Seog
Nagler, Arnon
Dimou, Maria
Demeter, Judit
Magagnoli, Massimo
Rodrigues, Liana
Wirtz, Oliver
Hiemeyer, Florian
Liu, Li
Koechert, Karl
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
Dreyling, Martin H.
BLOOD, 2018, 132
[5] Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
Dreyling, Martin
Santoro, Armando
Mollica, Luigina
Leppa, Sirpa
Follows, George A.
Lenz, Georg
Kim, Won Seog
Nagler, Arnon
Panayiotidis, Panayiotis
Demeter, Judit
Ozcan, Muhit
Kosinova, Marina
Bouabdallah, Krimo
Morschhauser, Franck
Stevens, Don
Trevarthen, David
Rodrigues, Liana
Hiemeyer, Florian
Wang, MingLu
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
BLOOD, 2018, 132
[6] Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
Zinzani, Pier Luigi
Santoro, Armando
Mollica, Luigina
Leppa, Sirpa
Follows, George A.
Lenz, Georg
Kim, Won Seog
Nagler, Arnon
Panayiotidis, Panayiotis
Demeter, Judit
Morschhauser, Franck
Rodrigues, Liana
Reeves, John
Hiemeyer, Florian
Miriyala, Ashok
Garcia-Vargas, Jose
Childs, Barrett H.
Dreyling, Martin H.
BLOOD, 2018, 132
[7] EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY
Zinzani, P. L.
Santoro, A.
Leppa, S.
Demeter, J.
Follows, G. A.
Lenz, G.
Kim, W. S.
Mollica, L.
Nagler, A.
Diong, C. P.
Provenciio, M.
Stevens, D. A.
Trevarthen, D.
Maagnoli, M.
Cupit, L.
Yin, S.
Hiemeyer, F.
Garcia-Vargas, J.
Childs, B. H.
Dreyling, M.
HAEMATOLOGICA, 2017, 102 : 314 - 315
[8] Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities
Dreyling, Martin
Santoro, Armando
Mollica, Luigina
Leppa, Sirpa
Follows, George
Lenz, Georg
Kim, Won Seog
Nagler, Arnon
Panayiotidis, Panayiotis
Demeter, Judit
Ozcan, Muhit
Kosinova, Marina
Bouabdallah, Krimo
Morschhauser, Franck
Stevens, Don A.
Trevarthen, David
Magagnoli, Massimo
Ishida, Tatiane
Lu, Cindy
Hiemeyer, Florian
Miriyala, Ashok
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
BLOOD, 2017, 130
[9] Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial
Dreyling, Martin
Panayiotidis, Panayiotis
Egyed, Miklos
Follows, George
Mollica, Luigina
Nagler, Arnon
Ozcan, Muhit
Santoro, Armando
Ishida, Tatiane
Lu, Cindy
Hiemeyer, Florian
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
BLOOD, 2017, 130
[10] Efficacy of Copanlisib Monotherapy in Patients With Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis From the CHRONOS-1 Trial
Martin, Peter
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 10 - 11

← 1 2 3 4 5 →